CVL-871
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Clinical data | |
---|---|
Routes of administration | Oral administration |
Drug class | Dopamine receptor agonist |
CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][3] It is taken via oral administration.[1] As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy.[1]
See also[edit]
- Tavapadon (CVL-751)
References[edit]
- ^ a b c d e "CVL 871 - AdisInsight".
- ^ a b Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.
- ^ "CVL-871 - Cerevel Therapeutics". 2 January 2020.
External links[edit]